
    
      It is a prospective, multicenter, randomized, controlled study to evaluate a scheme with and
      without a loading dose of 6 million international units of colistin, followed by a
      maintenance dose of 3 million international units every 8 hours intravenous. The study should
      be conducted in 3 hospitals in Chile, in critically patients presenting infection by
      multidrug Gram-negative bacteria and requiring be treated with colistin for at least 48
      hours. The objectives of the study are: to evaluate the clinical and microbiological
      response, and mortality.
    
  